Strategy has acquired 1,550 BTC for $101 million to increase our $BTC Reserve to ₿845,256. We have also increased our USD Reserve by $100 million to $1.0 billion. $MSTR $STRC https://t.co/1Zf1AVsP1H
Top-performing stocks tracked on X
Top stocks based on 1Y%
SN
Sandisk Corporation$SNDKRising onWhy it's trendingStrong bullish X conversationBacked by solid revenue growth
Hardware, Equipment & PartsBullish sentiment
SanDisk is up roughly 557% YTD and remains the best-performing S&P 500 stock of 2026, with the narrative anchored on NAND/HBM tightness, locked-in 2027 supply, and Mizuho raising its price target to $2,200. Bulls highlight SNDK trading at a 9.3x PEG with memory shortages projected through 2030 per SK Hynix Chey Tae-won, and over a third of FY27 bits already contracted. The recent 5% pre-market dip following AVGO's disappointing AI guidance is being treated as a buying opportunity, and chart watchers cite a clean 8-week-MA retest near $1,400 as the next defendable level. Sentiment is overwhelmingly conviction-buyer.
Proven numbers
SanDisk is the NAND-memory pure-play and the best-performing S&P 500 name this year — up roughly 540% YTD on the same memory-shortage thesis powering Micron. Hyperscaler capex is pulling NAND demand forward and Jensen Huang publicly calls memory 'the bottleneck' through 2027+. Q1 revenue tripled (+251% YoY) to $5.95B at a 69% operating margin and EPS of $24.43; the next-quarter estimate alone is $32.40, which makes the forward P/E look closer to 9x than the trailing 51x — that's the bull's '9.3x bargain of the century' framing. The pushback is the recent Friday sell-off on Broadcom's miss and concerns that Google's 'TurboVec' compression tool could pull NAND demand forward — neither structural, both valid near-term risks. The bet is the cycle still has 2027 visibility against a tape pricing the first hint of normalization.
AX
AXT, Inc.$AXTI
SemiconductorsBullish sentiment
AXTI unveiled an aggressive global capacity-expansion roadmap to double indium phosphide (InP) wafer output by retrofitting existing facilities, with Q1 2026 InP backlog surging to over $100M from minimal a year ago. Bulls cite the booming demand for high-speed optical communication materials across AI infrastructure as the key driver, plus AXTI's monopoly-like InP/GaAs wafer chokepoint. The stock pulled back 16% on the photonics sell-off after a 155% 3-month rally. Bears flag a $22.3M CEO insider sale (largest ever) and challenges getting China Ministry of Commerce approvals. Bulls treat $60-80 as a strong re-entry zone and conviction holders are accumulating.
Driven by hype
AXT (AXTI) is a small-cap specialty-substrate maker (indium phosphide / InP) reframed as the bottleneck supplier in the AI optical-interconnect chain — capex up, more GPUs, more optical transceivers, more InP wafers needed. The price action is once-a-cycle extreme: T12M +5017%, YTD +418%, sitting 155% above the 200-day moving average. Q1 revenue was just $27M (+39% YoY) at a -14% operating margin — the multiple at 43x sales prices the bottleneck thesis being right, not current cash flow. The recent catalyst: a late-May/early-June global capacity-expansion roadmap that retrofits idle facilities to roughly double global InP capacity, framed as the supply-side answer to AI optical demand. AXTI ranks ahead of AAOI in YTD performance (+130% vs +115%). Pushback is sharp: execution risk, crowded positioning, and a worst-three-performers tag on a recent down day signaling sharp reverses. The bet is the InP-bottleneck thesis stays the cohort narrative.
AB
Abivax S.A.$ABVX
BiotechnologyMixed sentiment⚠
Abivax obefazimod blowout UC data came out with 40% placebo-adjusted complete-response delta but the stock dropped sharply after misinterpretation of a cancer/NMSC safety table, briefly trading near $70 before recovering toward $96. Bulls including biotech analysts A_May_MD and Biohazard3737 frame the safety concerns as already adjudicated and treat the current valuation as deeply mispriced versus peak revenue projections of $3-5B. Acquisition rumors involving LLY, AZN and others are circulating with a potential $15-20B buyout cited. Bears highlight execution mistakes by the company in presenting the safety data and broader biotech sentiment fatigue.
Hinges on a big event
Abivax is the French biotech developing obefazimod (formerly ABX464), a small-molecule oral therapy targeting ulcerative colitis and Crohn's disease — positioned against the Rinvoq/Skyrizi standard of care with the structural pitch that obefazimod is 'a more effective Rinvoq without lab monitoring.' The stock is up 1,146% TTM but down 26% YTD, at the 67th percentile of the 52-week range — meaningful pullback after the Phase 3 maintenance UC readout sell-off triggered by safety-signal fears that bulls argue were over-extrapolated from the safety table presentation. Q1 2026 revenue was zero (pre-commercial), with operating margin deeply negative. The divergent sentiment reflects ongoing community debate on safety interpretation. No insider activity. The bet: if the safety-signal narrative resolves benignly, obefazimod's profile positions it for meaningful IBD share against JAK-inhibitor incumbents. The next FDA-engagement data point is the binary.
BE
Electrical Equipment & Parts
LI
Lumentum Holdings Inc.$LITEStrong FundamentalsStrong FundamentalsRevenue growing 90% YoY at strong marginsStreet coverage with positive forward estimatesConsistent chatter on X (7.4K/wk), no spike
Communication EquipmentAA
Applied Optoelectronics, Inc.$AAOIHot onWhy it's trendingX chatter picking upMoving on elevated volumeStrong bullish X conversation
SemiconductorsUnlimited access to free plan